Crohn's disease (CD) is a chronic recurrent intestinal inflammatory disorder of unknown etiology for which there is currently no established curative therapy. The main goal of CD treatment at present is to induce and maintain remission for as long as possible. Many CD patients experience frequent relapses and require surgery. CD patients need to have induction treatment every time they relapse, and also need to receive continuous maintenance treatment during periods of remission. Several approaches have been used as induction and maintenance treatment. Four kinds of therapies are now used mainly as induction treatment in Japan: total elemental enteral nutrition (EN), total parenteral nutrition (TPN), infliximab (IFX), and prednisolone (PSL). After the induction of remission, four therapies are now used as maintenance treatment in Japan; these include home elemental diet (HEN), 5-aminosalicylates (5-ASA), scheduled infliximab therapy, and immunomodulators (azathioprine or 6-mercaotoprine). These maintenance therapies can be used on their own or in combination. Recently, the development of biologic products has expanded treatment options for CD. Infliximab, a chimeric antibody to tumor necrosis factor-α , has been shown to be effective in inducing remission, and maintenance therapy with infliximab every eight weeks has become accepted as an effective maintenance treatment Rutgeerts et al. 2004 ). On the other hand, in Japan, TPN and EN have been approved as primary induction therapies for the treatment of active CD (Hiwatashi 1997) . EN is used as both an induction and maintenance treatment (Takagi et al. 2006 ). There are some reports that showed the efficacy of combination therapy of IFX and nutritional therapy (Matsumoto et al. 2005; Tanaka et al. 2006) . Matsumoto et al. showed that IFX was effective under TPN or EN (Matsumoto et al. 2005) . Tanaka et al. showed that CD patients with concurrent ED had a significantly higher response rate to IFX than those without EN (Tanaka et al. 2006) . However, there are no reports that have compared the effects on mid-and longterm prognosis among the induction and maintenance thera-pies used in Japan, especially between infliximab and EN.
Recently, it has been reported that several factors affect the prognosis of CD. Beaugerie et al. showed that factors predictive of a subsequent 5-year disabling course were age younger than 40 years, the presence of perianal disease, and the initial requirement for steroids (Beaugerie et al. 2006) . Wolters et al. showed that phenotype at diagnosis had predictive value for disease recurrence with upper gastrointestinal disease being the most important positive predictor (Wolters et al. 2006 ). Solberg et al., in a study involving 197 patients with CD, reported that terminal ileal location, stricturing, penetrating behavior and age younger than 40 years at diagnosis were independent risk factors for subsequent surgery (Solberg et al. 2007) . These previous cohort studies did not examine whether differences in therapy affected the prognosis. Therefore it is important to know to what extent differences between therapies for induction and maintenance affect relapse and surgical recurrence.
To determine the effects of each therapy and each variable, we conducted a prospective cohort study in CD patients. The main aim of this study was to evaluate the possible predictive factors, including induction and maintenance therapies, for the short-and long-term prognosis.
Patients and Methods

Patients
From April 2002 to March 2006, patients were recruited from Tohoku University Hospital. Patients had been diagnosed with CD either clinically, endoscopically, radiologically and/or histologically and fulfilled the diagnostic criteria for CD as defined by the Ministry of Health, Labour and Welfare of Japan (Yao et al. 2000) . We calculated the necessary sample size prior to the study initiation. About 70 patients had received medical therapies to induce remission for one year, and about 50% of the CD patients had relapsed for two years based on data from a retrospective follow-up study of patients with CD carried out at Tohoku University Hospital. Accordingly, we set the follow-up period as four years and examined approximately 280 patients as the sample size. This cohort study ran from April 2002 to March 2008. During this period, induction treatment was undertaken for 352 CD patients to induce remission at our hospital. Patients who failed to achieve remission (n = 50), and patients who were lost to follow-up within 12 months (n = 40) were excluded. Most patients who were lost to follow up were referrals from other clinics and hospitals. As they returned to the previous clinics and hospitals, we could not survey all their recurrences, so they were excluded. The remaining 262 patients with induced remission were enrolled in the study. This study was performed following the ethical guidelines for clinical studies of the Japanese Ministry of Health, Labor, and Welfare.
In order to achieve remission, patients were treated by one of the following four medical therapies, plus surgery when necessary. The treatment policy was based on the guidelines of the Investigation and Research Committee for Intractable Inflammatory Bowel Disease organized by the Japanese Ministry of Public Welfare (Iida 2007) . CD patients had undergone induction of remission through one of the four methods described below. Total elemental enteral nutrition (EN group) was the administration of an elemental diet (Elental TM , Ajinomoto, Tokyo, Japan) at a dose of 1500-2100 kcal/day for 6-8
weeks. The energy requirements of individual patients were calculated as 35 -40 kcal/kg ideal body weight/day. Total parenteral nutrition (TPN group) was administered through a subclavian vein catheter at a dose of 1500 -2100 kcal/day for 6 -8 weeks. TPN was chosen for patients with complications such as severe stenosis, complex fistulas, and severe perianal disease. Infliximab (IFX group) was administered at a dose of 5 mg/kg by intravenous infusion at weeks 0, 2, 6. IFX was mainly used for patients who did not respond to nutritional treatment or who had complex fistulas and severe perianal disease. Prednisolone (PSL group) was administrated orally or intravenously, starting with 40 mg/day, then tapered down by 5 mg/week until 20 mg/day was attained, and then tapered-off by 2.5 mg/week. PSL was mainly used for patients who did not want hospitalization. When necessary, surgical operation was carried out (Surgery group), which included bowel resections and strictureplasty but not seton drainage.
The indications for surgery were failed medical treatment, mechanical bowel obstruction, abscess, internal or external fistula, and perforation. TPN was used in most surgical patients to improve their nutritional state before surgery. Other therapies were also used before surgery.
Remission was defined as a Crohn's disease activity index (CDAI) of less than 150 (Sandborn et al. 2002) . We assessed whether a patient had reached remission at the times as follows. The patients of the EN or TPN groups were evaluated after 6-8 weeks of therapy. The patients of the PSL group were evaluated when the PSL dose had been tapered down to 20 mg/kg. The patients of the IFX group were evaluated at day 14 after the third injection. The patients of the Surgery group were evaluated when oral intake started (about 2 weeks after the operation).
After induction of remission, the patients were instructed to meet with their doctor at least once every 3 months. The disease activity was assessed according to CDAI. At each visit, the patient's CDAI scores were obtained, according to which we determined relapse. Relapse was defined as either when the patient's CDAI score exceeded 200, or when one of the four induction therapies started to control the patient's symptoms or disease activity.
Maintenance therapy
Patients received the following maintenance therapies that are commonly used in Japan. The maintenance therapies were used on their own or in combination until relapse or the last date of follow-up. Home elemental diet (HEN) was to supply half the amount of their daily allowance of calories by elemental diet (900-1200 kcal/day). 5-aminosalicylates (5-ASA) was administered orally at a dose of 1500-3000 mg/day. Scheduled infliximab was administered at a dose of 5 mg/kg by intravenous infusion every 8 weeks. Immunomodulators were administered orally, with azathioprine at a dose of 50-100 mg/day or 6-mercaotoprine at a dose of 30 -50 mg/day. This dose of azathioprine is far below the one recommended in Western countries but has been reported to be effective and safe for the maintenance of remission in the Japanese population (Hibi et al. 2003) . 5-ASA was used as basic maintenance therapy. To maintain the resolution of inflammation, HEN, scheduled infliximab, or immunomodulators were e m p l o y e d f o r p a t i e n t s w h o h a d f r e q u e n t r e c u r r e n c e s o r intractable disease.
Variables
The primary endpoint for this study was the occurrence of relapse and the occurrence of surgery. The influence of the following variables on the primary endpoint was evaluated: gender, age at enrollment, duration of disease (< 10 years, ≥ 10 years), frequency of previous relapse (high frequency, low frequency, first attack), location of disease (small bowel only, small bowel and colon, colon only), disease behavior (non stricturing & non-penetrating, stricturing, penetrating), perianal lesion, history of intestinal resection, CDAI before induction treatment (< 250, ≥ 250), C-reactive protein (CRP) level before induction treatment (below 5mg/dl, ≥ 5mg/dl), induction therapy (EN, TPN, IFX, PSL, surgery), and maintenance therapy (HEN, immunomodulators, 5-ASA, scheduled infliximab).
Location of disease was determined by colonoscopy, barium enema and small bowel X-ray. Patients were classified into non-stricturing & non-penetrating, stricturing, or penetrating based on the history of their disease at enrollment according to the Vienna classification (Gasche et al. 2000) . We used the patient's medical records to obtain the data of frequencies of previous relapses over the past five years. The patients were classified into three groups: high frequency (≥ 0.6 time/year), low frequency (< 0.6 times/year), or the first attack.
Statistical analysis
Proportional differences were analyzed by Pearson's chi-squared test. Comparisons of variables between two groups were performed by Mann-Whitney's test, and comparisons between more than three groups were performed by Kruskal-Wallis test. Both time to relapse and time to repeat resection surgery were calculated using a KaplanMeier curve. The influence of variables at inclusion was examined using the Cox multivariate hazard analysis. Results of analysis are presented as a hazard ratio (HR) with 95% confidence intervals (CI). Calculation was performed using SAS statistical software version 9.1 (SAS Institute, Cary, NC, USA). A p value below 0.05 was considered to be statistically significant.
Results
Study population
In total, 262 CD patients who had undergone induced remission were enrolled in the study. The median follow-up time was 47 months (range, 38-69 months). Thirty-four patients required surgical bowel resection. The details of their surgery were as follows: small bowel resection (n = 15), segmental colon resection (n = 8), ileocecal resection (n = 6), small bowel and colon resection (n = 4), subtotal colectomy (n = 1). The clinical characteristics of the patients included in the analysis are shown in Table 1 .
Relapse
Of the 262 patients, 165 (63%) relapsed during the follow-up period and the median duration until the first relapse was 19 months (mean 31 months, range 1-60). The significant predictors of the first relapse found in a multivariable Cox proportional hazard analysis are shown in Table 2 . (Fig. 1) . Among the maintenance therapies, only scheduled infliximab (HR = 0.24, 95% CI 0.12-0.48, p < 0.0001) protected against the first relapse (Fig. 2) .
Surgical recurrence
Sixty-one patients (23%) required surgical resection after a median duration of 37 months (mean 58 months, range 1-61). The variables associated with surgical recurrence, by univariate and multivariate analysis, are shown in Table 3 .
Male gender (HR = 2.44, 95% CI 1.18-5.04, p = 0.01) and high frequency of previous relapse (HR = 3.14, 95% CI 0.97-10.21, p = 0.05) were risk factors for surgical recurrence. In addition, penetrating (HR = 3.33, 95% CI 1.34-8.23, p = 0.009) or stricturing (HR = 6.60, 95% CI 2.84-15.34, p < 0.0001) disease behavior were associated with surgical recurrence.
Among induction therapies, PSL (HR = 4.15, 95% CI 1.26-13.61, p = 0.01) was associated with surgical recurrence. However, no significant difference was seen among the maintenance therapies.
Discussion
The main factors that strongly affected the first relapse were scheduled infliximab therapy (HR = 0.24, 95% CI 0.12-0.48, p < 0.0001), surgical induction (HR = 0.19, 95% CI 0.09-0.43, p < 0.0001) and high frequency of previous relapse (HR = 2.56, 95% CI 1.41-4.66, p = 0.002). Penetrating (HR = 3.33, 95% CI 1.34-8.23, p = 0.009) and stricturing (HR = 6.60, 95% CI 2.84-15.34, p < 0.0001) disease behavior were main risk factors of surgical recurrence.
Our data showed that scheduled infliximab therapy was the most effective maintenance therapy used in a real clinical setting. It is difficult to study each therapy for a long term by a randomized clinical trial, so we examined the effect of each therapy in a prospective cohort study. Only scheduled infliximab therapy showed a significantly low risk of subsequent relapse among the four maintenance therapies, while HEN, 5-ASA, and immunomodulators did not seem to prevent subsequent relapse and surgery effectively. To our knowledge, this is the first report showing that scheduled infliximab therapy was superior to other maintenance therapies including HEN in respect to the midand long-term prognosis. In many western previous studies, it has been shown that 8-weekly infusions of infliximab are effective in maintaining remission compared with placebo Rutgeerts et al. 2004 ). In addition, it has been shown that scheduled infliximab therapy reduces hospitalizations and the need for surgery (Lichtenstein et al. 2005) . According to the guidelines of the Investigation and Research Committee for Intractable Inflammatory Bowel Disease organized by the Japanese Ministry of Public Welfare, the use of infliximab is recommended for CD patients refractory to nutritional therapy (Iida 2007) . We have previously shown the efficacy of HEN for the maintenance of remission in a randomized controlled study (Takagi et al. 2006 ). However, because scheduled infliximab therapy was superior to other maintenance therapies including HEN in the present study, it is time to consider whether the Japanese guidelines should be changed.
Among the medical induction therapies, the patients in the TPN group were significantly protected from a first relapse and, although it did not reach statistical significance (p = 0.06), the EN group had a tendency to be protected from the first relapse. Nutritional therapies were not inferior to IFX and PSL as induction therapies only in a first relapse. On the other hand, the present IFX induction group had a high relapse rate compared to the other induction therapies. With respect to the clinical characteristics at inclusion, patients in the IFX and PSL groups were older and had had a longer duration of disease. In addition, 60% of the IFX group had had a high frequency of previous relapse. Past studies have shown that younger age at the time of infliximab administration and shorter duration of CD are associated with a favorable therapeutic effect of infliximab (Kugathasan et al. 2000; Vermeire et al. 2002) . This selection bias may be a reason why the IFX group had a high relapse rate in this report.
The surgery group had the lowest risk of subsequent relapse among the induction therapy groups. This is not an unexpected result, because only surgical resection can relieve active intestinal lesions. In a previous popula- (27) 18 (23) 35 (60) 19 (45) 10 (29) Low (< 0.6/yr) 107 (41) 14 (29) 38 (48) 21 (36) 21 (50) 13 (38) Location of the disease Small bowel 46 (18) 13 (27) 15 (19) 2 (3) 7 (17) 9 (26) 0.036 Small bowel and colon 167 (64) 27 (56) 53 (66) 44 (76) 23 (55) 20 (59) Colon 49 (19) 8 (17) 12 (15) 12 (21) 12 (29) 5 (15) Diseasebehavior Non stricturing/penetrating 108 (41) 22 (46) 39 (49) 18 (31) 18 (43) 11 (32) 0.09 Penetrating 81 (31) 10 (21) 21 (26) 26 (45) 9 (21) 14 (41) Stricturing 73 (28) 16 (33) 20 (25) 14 (24) 15 (36) tion-based study, it was suggested that surgery was associated with the longest remissions (Silverstein et al. 1999 ). In addition, in this study, TPN was also given to almost all of the resection patients before surgery. TPN usually improves the nutritional state in terms of the serum albumin levels and weight, which would also contribute to an improved relapse rate.
The frequency of previous relapse showed a tendency to increase the risk of a subsequent relapse and surgery. A high CDAI before induction therapy influenced the rate of the first relapse. These results suggest that the previous relapse rate and a high disease activity index are predictive of the future course of the disease. This finding is similar to those described in previous reports (Munkholm et al. 1995) . Munkholm et al. reported that the relapse rate for any 1 year influenced the relapse rate the following year. Our data suggest that patients with a high disease activity index or a high previous relapse rate should be treated by early intensive treatment. One hundred sixty five patients (63%) relapsed during the follow-up period (mean 47 months), and the median duration of time to the first relapse was 19 months. This relapse rate is lower than those reported in previous studies (Lapidus et al. 1998; Wolters et al. 2006; Henriksen et al. 2007 ). Several possible explanations for this are as follows. First, previous studies collected data before the newer biological treatments became more widely used. Second, EN or TPN was delivered for longer durations in our patients than in previous reports. Third, apart from the first attack, we were able to select the treatment based on the response to the previous treatment experience. This might have resulted in a better response to the therapy.
Our study has some potential limitations. First, it was a single center cohort study, and it included a selective bias. So the present results may be representative of a more restrictive patient population compared to a populationbased cohort. But it is difficult to study predictive factors for mid-and long-term prognosis by randomized clinical trial in practice. We did not assess the study by blinded physicians, which may create a bias. Second, in this cohort study, 60 patients (23%) were naive to CD treatment. The other 95 patients had high frequencies of previous relapse. They had received many treatments previously, so we could not include all of the previous medications and could not incorporate them into the analysis. Third, smoking is one of the increasing risk factors for recurrence in CD (Cottone et al. 1994 ). Because we could not collect all data of the smoking status, we did not include smoking status as one of the variables.
In conclusion, scheduled infliximab therapy is the most effective maintenance therapy in a real clinical setting with respect to the mid-and long-term prognosis.
